QuEra Computing announced that all three projects it supports have progressed to Phase Two of Wellcome Leap’s Quantum for Bio Challenge. This initiative funds multidisciplinary teams exploring quantum applications in healthcare and biology, with $40 million allocated for research and $10 million in prizes for successful proofs of concept. The projects aim to leverage quantum computing to address complex medical challenges and accelerate advancements in human health.
In Phase One, teams focused on developing quantum algorithms to tackle biology and healthcare issues. QuEra’s projects were among eight selected to advance from an initial 12, showcasing notable advancements within targeted resources. Phase Two will involve large-scale simulations of these algorithms on high-performance classical computing platforms, simulating quantum algorithms for 30-40 qubits. Teams must also secure quantum hardware expertise to qualify for Phase Three.
QuEra is collaborating on three groundbreaking projects: drug discovery for myotonic dystrophy with the University of Nottingham, Phasecraft, and QuEra; quantum simulations for drug discovery pipelines, led by Harvard, MIT, and QuEra; and protein interaction analysis for Alzheimer’s and Parkinson’s diseases, with partners including MIT, Argonne National Lab, and qBraid. Each effort exemplifies the transformative potential of quantum computing in addressing critical biological and medical challenges.
QuEra, a leader in neutral-atom quantum computing, provides the only publicly accessible platform of its kind and continues to integrate its expertise in quantum algorithms to drive impactful medical breakthroughs.
For further details, refer to the press release here.
December 3, 2024
